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Abstract: Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of
psoriatic arthritis (PsA). It provides an alternative option for patients who have had an
inadequate response and tolerance to other disease modifying antirheumatic drugs
(DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the
management of treatment resistant disease, and is reported to improve enthesitis, dactylitis,
and radiographic progression. Tofacitinib is also associated with an increased risk of serious
infections, malignancy, and laboratory abnormalities. There is currently a large armamentar-
ium of therapies for psoriatic arthritis, and choosing among treatments can be challenging.
Due to this wide selection, a thorough assessment of psoriatic disease phenotype, patient
preference, disease presentation, and comorbidities is critical. This review addresses key
considerations in patient selection for the treatment of PsA with tofacitinib.
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Introduction
Psoriatic arthritis (PsA) is a chronic, inflammatory musculoskeletal disease that is
characterized by peripheral arthritis, enthesitis, dactylitis, and spondylitis with or
without nail and skin lesions.1,2 It is a systemic disease that develops in up to 40% of
psoriasis patients in their lifetime3–5 with manifestations that include pain, swelling,
stiffness, and entheses of the peripheral joints and/or axial skeleton. Dactylitis, fusiform
full thickness swelling of fingers or toes, can develop in about half of individuals with
PsA. In addition, it is also associated with significant comorbidities such as diabetes
mellitus, depression, hypertension, cardiovascular disease, and decreased quality of
life.1,5 Although the pathogenesis of PsA has not been fully elucidated, it likely results
from a combination of genetic, environmental, and immunologic factors.6
PsA is a heterogeneous disease with diverse clinical presentations, making
early diagnosis and management challenging.7 There are five distinct clinical
subtypes: the oligoarticular subtype affects four or fewer joints in an asymmetric
distribution; the polyarticular subtype affects at least five joints, is symmetrical,
and most similar to rheumatoid arthritis; the distal subtype involves the distal
interphalangeal joints of the hands and feet; the arthritis mutilans subtype is the
most severe and characterized by bone resorption or osteolysis that results in
significant deformities; and the spondyloarthritis subtype, which primarily affects
the spine and sacroiliac joints.8 Effective treatment of this rheumatologic disease
is critical to minimize damage,9 negative impact on quality of life and to mitigate
the risk of comorbid disease.
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Current PsA treatment guidelines include nonsteroidal
anti-inflammatory drugs, glucocorticoids, oral small mole-
cules (methotrexate, sulfasalazine, cyclosporine, lefluno-
mide, apremilast), tumor necrosis factor alpha (TNF-α)
inhibitors (etanercept, adalimumab, infliximab, golimu-
mab, certolizumab), interleukin (IL) 12/23 inhibitors (uste-
kinumab), IL-17 inhibitors (secukinumab, ixekizumab),
CTLA4-Ig (abatacept), and the janus kinase inhibitor
(tofacitinib).10–12 Each therapy has a distinct safety and
efficacy profile, and treatment plans should be individua-
lized and optimized by taking into account clinical pre-
sentation and medical history. While there are many
treatment options for the management of PsA, it can be
challenging for practitioners to select among therapies.
This review addresses key considerations in patient selec-
tion for the treatment of psoriatic arthritis with tofacitinib.
Practical considerations
Tofacitinib (Xeljanz, Pfizer Inc.) is an orally administered
inhibitor of predominantly JAK1 and JAK3, with func-
tional selectivity over JAK2.4,13,14 Blockade of the JAK
receptor downregulates the production of cytokines impor-
tant in the pathogenesis of PsA, including TNF-α, IL-17,
IL-6, IL-23.14,15 Tofacitinib is currently approved for the
treatment of PsA, rheumatoid arthritis, and ulcerative
colitis.16
Tofacitinib is indicated for patients with active PsA
who have had a poor response or intolerance to metho-
trexate or other disease modifying antirheumatic drugs
(DMARDs). Since tofacitinib has not been evaluated as a
monotherapy in PsA, it is recommended that it be used in
combination with a conventional synthetic DMARDs
(csDMARD), such as methotrexate, sulfasalazine, and
leflunomide. Tofacitinib should not be used in combination
with biologic DMARDs or potent immunosuppressants,
such as cyclosporine and azathioprine due to risk of
added immunosuppression.
Tofacitinib is available as a 5 milligram (mg) or 10 mg
immediate release tablet and as an 11 mg extended release
tablet. The recommended dosing for both PsA and rheu-
matoid arthritis is immediate release 5 mg twice daily or
extended release 11 mg once daily in combination with
non-biologic DMARDs. For ulcerative colitis, the recom-
mended dose is 10 mg twice daily for 8 weeks; followed
by 5 or 10 mg twice daily, depending on the patient’s
response. Dose adjustments are recommend for patients
concomitantly taking medications that undergo CYP3A4
inhibition as tofacitinib is primarily metabolized by this
pathway.16
Tofacitinib has no contraindications, but there are
FDA-required black box warnings for an increased risk
of serious infections and malignancies.16 Patients should
be evaluated for latent or active tuberculosis infection
prior to treatment with tofacitinib, and anti-tuberculosis
therapy should occur prior to initiating this medication.
Due to the increased risk of serious infections, the risks
and benefits of therapy should be weighed in patients with
a history of chronic or recurrent infections. Additionally,
lymphomas and other malignancies have been observed in
patients treated with tofacitinib and an increased risk of
EBV-associated post-transplant lymphoproliferative dis-
ease was observed in renal transplant patients.
In February 2019, the FDA reported a safety alert
regarding the increased risk of pulmonary embolism and
death for the 10 mg twice daily dose of tofacitinib, which
was noted during a safety trial in patients with rheumatoid
arthritis.17 For this reason, patients taking the 10 mg twice
daily dose were decreased to a dose of 5 mg twice daily.
Further data is needed to elucidate this risk, and the safety
trial is anticipated to be completed by the end of 2019.
Tofacitinib 10 mg twice daily is not an approved dose for
the treatment of PsA. No data has been provided on the
risk of tofacitinib 11 mg extended release.
Laboratory monitoring is required due to potential
changes in lymphocytes, neutrophils, hemoglobin, liver
enzymes, and lipids. Absolute lymphocyte counts (ALC)
should be monitored at baseline and every three months
thereafter. Absolute neutrophil counts (ANC) should be
measured at baseline, after four to eight weeks of treatment,
and every three months thereafter. Hemoglobin is monitored
at baseline, after four to eight weeks of treatment, and every
three months thereafter. Liver function tests (LFTs) should
be routinely monitored, and lipids should be assessed four
to eight weeks following initiation of therapy.
Psoriatic arthritis clinical trials
Two phase III randomized controlled trials (RCTs) evaluated
the efficacy and safety of tofacitinib in PsA: OPAL Broaden11
andOPALBeyond.12 In both studies, the co-primary endpoints
were the proportion of patients with a 20% improvement of the
American College of Rheumatology criteria (ACR20) at three
months and the change frombaseline in theHealthAssessment
Questionnaire-Disability Index (HAQ-DI) at three months.
The co-primary efficacy endpoints were achieved in both
RCTs (Table 1).
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OPAL Broaden was a 12-month double-blind, active-
controlled and placebo-controlled, phase 3 trial investigating
the efficacy of tofacitinib compared to placebo or adalimu-
mab in patients with active PsAwith an inadequate response
to csDMARDs. Inclusion criteria required TNF-α inhibitor
naivety. Patients were randomly assigned to receive either
tofacitinib 5 mg or 10 mg twice daily, adalimumab 40 mg
subcutaneously every two weeks, or placebo with a blinded
switch to either 5 mg or 10 mg at three months. Patients were
also required to receive a stable dose of csDMARD through-
out the trial. This study was completed by 373 patients. With
regards to the co-primary endpoints, a significantly greater
proportion of patients at month three achieved ACR20 on
tofacitinib (5 mg: 50%, p=0.01; 10 mg: 61%, p<0.001)
compared to placebo (33%); for reference, ACR20 in the
adalimumab arm was 52%. Tofacitinib was superior to pla-
cebo with respect to the mean change from baseline HAQ-DI
score (5 mg: −0.35, p=0.006; 10 mg: −0.40, p<0.001) versus
placebo (−0.18); for reference mean HAQ-DI change with
adalimumab was −0.38.
Secondary endpoints of ACR50 (5 mg: 28%, p<0.001;
10 mg: 40, p<0.001; placebo: 10%), ACR70 (5 mg: 17%,
p=0.004; 10 mg: 14%, p=0.02; placebo: 5%), and an
improvement in the Psoriasis Area and Severity Index
(PASI) of at least 75% (PASI75; 5 mg: 43%, p<0.001;
10 mg: 44%, p<0.001; placebo: 15%) were assessed and
both doses of tofacitinib were found to be superior to
placebo. The change in the Leeds Enthesitis Index (LEI)
was found to be superior to placebo with tofacitinib 10 mg
(−1.5 versus −0.4, p<0.001) but not with the tofacitinib 5 mg
dose (−0.8 versus −0.4). Additional pre-specified secondary
endpoints of Dactylitis Severity Score (DSS), Medical
Outcomes Study 36-Item Short Form Health Survey (SF-
36), and the Functional Assessment of Chronic Illness
Therapy–Fatigue (FACIT-F) were in the same direction as
the primary endpoints but could not be assessed for signifi-
cance due to hierarchical statistical testing of secondary
endpoints.11,18 Radiographs of the hands and feet were
assessed at baseline and 12 months using the van der
Heijde-modified Total Sharp Score (mTSS). At 12 months,
91–98% of patients across all treatment groups met the radio-
graphic criteria for nonprogression of joint damage, defined
as a change in mTSS of ≤0.5, ≤0, or ≤0.66 from baseline.11,19
In OPAL Broaden, adverse events (AEs) occurred
more frequently with tofacitinib and adalimumab than
placebo at three months (5 mg: 39%, 10 mg: 45%, adali-
mumab: 46%, placebo: 35%). The most common adverse
events were nasopharyngitis, upper respiratory tract infec-
tion, and headache. Serious adverse events (SAEs)
occurred more frequently with tofacitinib 5 mg at three
months (5 mg: 3%, 10 mg: 1%, adalimumab: 1%, placebo:
1%). At 12 months, three tofacitinib patients reported
serious infections (influenza, appendicitis, and pneumonia)
compared to one adalimumab patient (herpes simplex and
Table 1 Summary of key Phase III clinical trial results of tofacitinib for the treatment of psoriatic arthritis at month three
Endpoints OPAL Broaden Opal Beyond
Placebo
(n=105)
Tofacitinib
5 mg (n-107)
Tofacitinib
10 mg
(n=104)
Adalimumab
40 mg Q2W
(n=106)
Placebo
(n=131)
Tofacitinib
5 mg
(n=131)
Tofacitinib
10 mg
(n=132)
Primary Endpoints
ACR20 33% 50% 61% 52% 24% 50% 47%
ΔHAQ-DI −0.18 −0.35 −0.40 −0.38 −0.14 −0.39 −0.35
Secondary Endpoints
PASI75 15% 43% 44% 39% 14% 21% 43%
ACR50 10% 28% 40% 33% 15% 30% 28%
ACR70 5% 17% 14% 19% 10% 17% 14%
ΔLEI −0.4 −0.8 −1.5 −1.1 −0.5 −1.3 −1.3
ΔDSS −2.0 −3.5 −5.5 −4.0 −1.9 −5.2 −5.4
ΔSF-36 2.1 5.2 5.2 5.2 1.7 5.0 4.1
ΔFACIT-F 3.3 7.0 6.0 6.0 3.0 7.0 5.8
Notes: All endpoints tested at three months; ACR20/50/70: a minimum of 20, 50, and 70% improvement in the ACR response; PASI75: at least a 75% improvement in the
PASI score; ΔHAQ-DI/LEI/DSS/SF-36/FACIT-F: change from baseline score.
Abbreviations: ACR, American College of Rheumatology; DSS, Dactylitis Severity Score; HAQ-DI, Health Assessment Questionnaire Disability Index; FACIT-F, Functional
Assessment of Chronic Illness Therapy–Fatigue; LEI, Leeds Enthesitis Index; PASI, Psoriasis Area-and-Severity Index; SF-36, Study 36-Medical Outcomes Study 36-Item Short
Form Health Survey.
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streptococcal pyoderma). Herpes zoster occurred in four
patients, all whom were treated with tofacitinib. Four
cancers (bladder transitional cell carcinoma, squamous
cell carcinoma of the vulva, invasive ductal breast carci-
noma, and basal cell cancer) were reported, all in patients
who received tofacitinib. One death due to cardiac arrest
was reported in a patient treated with tofacitinib 5 mg.
At three months, neutrophil counts were more reduced
in the active treatment groups than placebo. Elevations in
alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) three or more times the upper limit of normal
was observed in tofacitinib and adalimumab groups.
OPAL Beyond was a six-month RCT evaluating tofa-
citinib compared to placebo in patients with active PsA
who had an inadequate response to TNF-α inhibitors. This
study was completed by 345 patients. Similar to the results
found in OPAL Broad, a significantly greater proportion of
patients at month three achieved ACR20 on tofacitinib
(5 mg: 50%, p<0.001; 10 mg: 47%, p<0.001) compared
to placebo (24%). Tofacitinib was also found to be super-
ior with respect to the mean change from baseline HAQ-
DI score (5 mg: −0.39, p<0.001; 10 mg: −0.35, p<0.001)
compared to placebo (−0.14).
Additionally, both doses of tofacitinib were superior to
placebo at three months with respect to ACR50 (5 mg:
30%, p=0.003; 10 mg: 28%, p=0.007; placebo: 15%), but
not ACR70 (5 mg: 17%; 10 mg: 14%; placebo: 10%).
With regard to PASI75, the 10 mg dose of tofacitinib
was superior to placebo (5 mg: 21%; 10 mg: 43%,
p<0.001; placebo: 14%), but not the 5 mg dose. Pre-
specified endpoints of resolution of LEI, and improve-
ments in DSS, SF-36, FACIT-F were in the same direction
as the primary endpoints but could not be analyzed for
statistical significance due to hierarchical statistical testing
of secondary endpoints.12,20
In OPAL Beyond, the rate of AEs was higher with
tofacitinib than placebo at three months (5 mg: 55%,
10 mg: 53%, placebo: 44%). The rates of SAEs were 1%
for tofacitinib 5 mg, 2% for 10 mg, and 2% for placebo.
The most common AEs were upper respiratory infection,
nasopharyngitis, and headache. Four tofacitinib patients
reported serious infections (bilateral pyelonephritis, paro-
titis, pneumonia, and oral candidiasis). Herpes zoster
infection occurred in three patients, all of whom were
treated with tofacitinib. Two major adverse cardiovascular
events (MACE) occurred in patients treated with tofaciti-
nib (myocardial infarction in 5 mg and ischemic stroke in
10 mg). No deaths or cancers were reported.
Changes from baseline were similar across all groups
for hemoglobin and lymphocyte counts at three months.
Changes in neutrophil, platelet, creatinine, creatine kinase,
and lipid values were observed to be dose dependent. At
six months, elevations of AST and ALT greater than the
upper limit of normal were observed in patients treated
with tofacitinib (AST: 30%, ALT: 32%), and elevations
three more times the upper limit of normal was also
observed in six patients.
OPAL Balance is an ongoing, open-label, long-term
extension (LTE) study evaluating the safety and efficacy
of tofacitinib in patients with PsA.5,21,22 Patients from
OPAL Broaden and OPAL Beyond were invited to parti-
cipate in a three year LTE study within three months of
completing or discontinuing the parent study. This study
treated 686 patients, who were treated with tofacitinib
5 mg BID or 10 mg BID, depending on treatment
response. Primary endpoints were incidents and severity
of adverse events and changes in baseline laboratory
values. The secondary endpoint was long-term efficacy
measured up to month 30. By month 36, 73.2% of patients
reported AEs (n=502), 10.5% of patients reported SAEs
(n=72), and 2.8% reported a herpes zoster event (n=19).
MACE was observed in 0.3% of patients (n=2) and malig-
nancies were reported in 1.9% of patients (n=13). Four
deaths were reported that were determined to be unrelated
to treatment (pancreatic carcinoma, acute cardiac failure,
chronic obstructive pulmonary disease, and pulmonary
embolism). Four latent tuberculosis adverse events were
reported in patients with a previously negative
QuantiFERON. Over 36 months of data demonstrated
that the safety profile was similar to those reported in
previous trials. No new safety risks were reported and
efficacy was maintained.5,22
A 52 week, randomized, double-blind, phase III clin-
ical trial evaluated the safety and efficacy of tofacitinib in
Japanese patients with moderate to severe plaque psoriasis
(n=87), PsA (n=12), or both (n=5). Patients were rando-
mized 1:1 to tofacitinib 5 mg or 10 mg twice daily for
16 weeks, open-label 10 mg twice daily for 4 weeks, then
the dose was adjust to tofacitinib 5 mg or 10 mg at the
investigator’s discretion to 52 weeks. The primary end
points were PASI75, Physician’s Global Assessment
(PGA) of “clear” or “almost clear” for psoriasis, and
ACR20 for PsA. At week 16, 62.8% of patients treated
with tofacitinib 5 mg and 72.7% of patients treated with
tofacitinib 10 mg achieved PASI75. The PGA primary end
point was achieved by 67.4% and 68.2% of patients,
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respectively. ACR20 was achieved by all patients with
PsA. The most common AEs were nasopharyngitis and
herpes zoster, with 17% herpes zoster incidence rate.
There were no cardiovascular events, deaths, or malignan-
cies reported.23
Psoriasis clinical trials
Multiple, randomized clinical trials have been conducted
to evaluate the efficacy, safety, and tolerability of tofaciti-
nib in patients with plaque psoriasis (Table 2).
A phase 2b randomized, placebo-controlled, 12-week
clinical trial evaluated the efficacy and safety of tofacitinib
in patients with moderate-to-severe chronic plaque psor-
iasis. Patients received 2 mg, 5 mg, 15 mg twice daily or
placebo. The primary endpoint was the proportion of
patients achieving PASI75 at week 12. PASI75 response
rates were significantly higher for all tofacitinib groups
compared to placebo (2 mg: 25.0%, 5 mg: 40.8%, 15 mg:
66.7%, placebo: 2.0%). Higher response rates for PASI50,
PASI90, and PGA were also seen across all tofacitinib
groups compared to placebo. This study demonstrated
that short-term treatment with tofacitinib could be an
effective treatment in patients with moderate-to-severe
plaque psoriasis.24,25
Two pivotal multi-center, randomized, placebo-con-
trolled, blinded phase III studies, OPT Pivotal 1 and OPT
Pivotal 2, were conducted to evaluate the efficacy of 5 mg
and 10 mg tofacitinib compared to placebo for patients with
moderate-to-severe chronic plaque psoriasis.26–29 The two
primary endpoints were PASI75 and PGA response at
16 weeks. Both studies achieved the coprimary endpoints,
with a significantly greater proportion of patients achieving
PASI75 (OPT Pivotal 1: 5 mg: 39.9%, 10 mg: 59.2%,
placebo: 6.2%; OPT Pivotal 2: 5 mg: 46.0%, 10 mg:
59.6%, placebo: 11.4%) and PGA (OPT Pivotal 1: 5 mg:
41.9%, 10 mg: 59.2%, placebo: 9.0%; OPT Pivotal 2: 5 mg,
46.0%, 10 mg: 59.1%, placebo: 10.9%) compared to pla-
cebo. A dose-dependent improvement was observed with a
greater proportion of the tofacitinib 10 mg group achieving
PASI75 and PGA response, and in a shorter amount of time,
than the tofacitinib 5 mg group. Secondary endpoints of
percentage change from baseline of body surface area
Table 2 Summary of key clinical trial results of tofacitinib for the treatment of plaque psoriasis
Study Phase Intervention PASI 75 PGA
Phase 2b 2 mg 25.0% 24.5%
II 5 mg 40.8% 40.8%
10 mg 66.7% 72.9%
Placebo 2.0% 10.0%
OPT 1 5 mg 39.9% 41.9%
III 10 mg 59.2% 59.2%
Placebo 6.2% 9.0%
OPT 2 5 mg 46.0% 46.0%
III 10 mg 59.6% 59.1%
Placebo 11.4% 10.9%
OPT Retreatment
Withdrawal Period 5 mg 56.2% 49.9%
III 10 mg 62.3% 63.9%
Placebo 5 mg 23.3% 22.9%
Placebo 10 mg 26.1% 18.0%
Retreatment Period 5 mg 36.8% 44.8%
10 mg 61.0% 57.1%
OPT Compare 5 mg 39.5% 47.1%
IIII 10 mg 63.6% 68.2%
Etanercept 58.8% 66.3%
Placebo 5.6% 15.0%
Notes: Phase 2b and OPT Compare endpoints tested at week 12; OPT 1, OPT 2, and OPT Retreatment endpoints tested at week 16; PASI 75, at least 75% reduction in the
Psoriasis Area and Severity Index score; PGA, Physician’s Global Assessment; Dosing of etanercept: 50 mg SQ twice weekly; tofacitinib dosed twice daily.
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(BSA), Dermatology Life Quality Index (DLQI), Patient
Global Assessment (PtGA), Itch Severity Item (ISI), Nail
Psoriasis Severity Index (NAPSI) improvement, and
PASI90 were also met.
OPT Retreatment was a randomized, blinded, parallel-
group, phase III trial evaluating the effects of tofacitinib
5 mg and 10 mg withdrawal and re-treatment in patients
with plaque psoriasis. The primary efficacy endpoints were
the proportion of patients maintaining a PASI75 and PGA
response in the withdrawal period, and the proportion of
patients achieving a PASI75 and PGA response in the
retreatment period, after relapsing in the withdrawal
phase. At the end of the withdrawal phase a greater per-
centage of tofacitinib patients maintained PASI75 (5 mg:
56.2%, 10 mg: 62.3%, placebo 5 mg: 23.3%, placebo
10 mg: 26.1%,) and PGA response (5 mg: 49.9%,
10 mg: 63.9%, placebo 5 mg: 22.9%, placebo 10 mg:
18.0%). In the retreatment phase, 36.8% and 61.0% of
tofacitinib 5 mg and 10 mg, respectively, achieved
PASI75; and 44.8% and 57.1% achieved PGA responses.
In sum, this study indicated that tofacitinib could be effi-
cacious after withdrawal and retreatment.30,31
OPT Compare was a randomized, placebo-controlled,
12 week, non-inferiority phase III trial comparing tofaci-
tinib 5 mg and 10 mg to high dose entanercept or placebo
in patients with moderate-to-severe plaque psoriasis. The
primary endpoints were the proportion of patients with a
PASI75 and the proportion of patients with a PGA
response at 12 weeks of treatment. A PASI75 at week 12
was achieved by 39.5% of tofacitinib 5 mg, 63.6% of
tofacitinib 10 mg, 58.8% of entanercept, and 5.6% of
placebo. Both tofacitinib and etanercept achieved signifi-
cant PGA reductions compared to placebo (5 mg: 47.1%,
10 mg: 68.2%, etanercept: 66.3%, placebo: 15.0%).
Tofacitinib 10 mg was found to be non-inferior to etaner-
cept, but tofacitinib 5 mg was not shown to be non-inferior
to etanercept.32
Although study results demonstrated that both the 5mg and
10 mg doses were effective in treating plaque psoriasis,33–35
the 10mg dose was proven to bemore efficacious.36 However,
this higher dose is associated with increased safety concerns,
leading the FDA to decline approval of tofacitinib for moder-
ate-to-severe plaque psoriasis.27,37
Safety
Integrated safety analyses of phase III studies38 and the
LTE study22 found tofacitinib to be well tolerated in
patients with psoriatic arthritis with a safety profile that
is comparable to other biologics.11,39 The adverse events
reported in psoriatic arthritis trials were similar to those
reported for rheumatoid arthritis and psoriasis.38,39
The most common adverse events reported in the phase
III trials were upper respiratory infections, nasopharyngitis,
and headaches.11,12 Tofacitinib has been associated with an
increased risk of herpes zoster, which occurred in the active
treatment group of both trials. There is also an increased
risk of serious infections, including tuberculosis, pneumo-
nia, and influenza.
Due to the immunosuppression induced by tofacitinib,
this medication may increase the risk of malignancies.40
No cancers were observed in OPAL Beyond, however in
Opal Broaden, 4 cancers were reported in patients who
received tofacitinib compared to zero patients in the pla-
cebo or adalimumab group. Two of the malignancies were
reported within 30 days of the first dose of tofacitinib.
Furthermore, the three OPAL trials reported adverse car-
diovascular events of myocardial infarction and ischemic
stroke (Table 3).
Tofacitinib has also been associated with a variety of
laboratory abnormalities. Due to the blockade of myelo-
poietic growth factor signals,3 there is an increased risk of
cytopenia. Neutropenia and anemia have been observed,
but are mild at lower doses. In addition, liver enzyme
levels were found to be elevated compared to placebo.
Tofacitinib is also associated with a dose-dependent
increase in lipid parameters, including total cholesterol,
low-density lipoprotein (LDL), high-density lipoprotein
(HDL), and triglycerides.41,42 In OPAL Beyond, dose
dependent changes were also observed in lymphocyte
count, platelet count, creatinine, and creatine kinase. For
these reasons, routine laboratory monitoring is recom-
mended, and clinicians should follow up on any
abnormalities.
The long-term safety of tofacitinib in psoriatic arthritis
was evaluated in OPAL Balance. No new safety risks were
identified and tofacitinib’s safety profile was similar to
phase III trials.
Discussion
Treatment options in PsA have expanded, and choosing
among treatments can be a complex decision. Due to the
heterogeneous pathogenesis of PsA, patients may not
achieve satisfactory disease control with available thera-
pies, which creates a need for alternative treatment
options. While TNF-α inhibitors are recommended as
first line treatment for active PsA,10,13 tofacitinib can
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provide an alternative option when injectable biologics are
either contraindicated or provide an inadequate response.10
Prior to initiating tofacitinib, a thorough assessment of
patient preference, disease presentation, and comorbidities
is critical.
As an oral medication, tofacitinib provides patients
with an alternative to parenteral therapy. Tofacitinib has
a similar efficacy profile to biologics, while also offering
patients convenience and independence, potentially
improving medication compliance and decreasing health-
care costs. Tofacitinib is an alternative to apremilast, an
oral phosphodiesterase-4 inhibitor also indicated for psor-
iatic arthritis.43 While apremilast has a favorable safety
profile, its efficacy is considerably lower than biologics,44
whereas tofacitinib has been demonstrated to have efficacy
comparable to biologics.
Tofacitinib can also be considered in patients with
difficult to treat disease. The results of OPAL Beyond,
which included patients with inadequate response to at
least one TNF-α inhibitor, indicate that tofacitinib may
be effective in patients with treatment-resistant psoriatic
arthritis. In addition, both phase III clinical trials reported
improvement in enthesitis and dactylitis, as measured by
the LEI and DSS, respectively. These clinical manifesta-
tions are associated with an increased burden of disease
and decreased quality of life, underscoring the importance
of tofacitinib’s efficacy in these domains.5,45
Furthermore, OPAL Broaden evaluated the effect of
tofacitinib on radiographic outcomes and reported that
greater than 90% of patients achieved radiographic
nonprogression.11,19 The overall rate of radiographic pro-
gression was low in all patients.
Although tofacitinib has not received an FDA indica-
tion for plaque psoriasis, it has demonstrated efficacy in
patients with moderate-to-severe chronic plaque psoriasis
in multiple clinical trials, as well as in psoriatic arthritis
patients with skin manifestations. Tofacitinib can be con-
sidered as a treatment option in patients with psoriatic
arthritis and comorbid skin disease. Tofacitinib is also
being investigated as a treatment for alopecia areata, viti-
ligo, atopic dermatitis, and dermatomyositis and may be
considered in psoriatic arthritis patients with comorbid
disease.46,47
There are a number of considerations with regards to
tofacitinib’s safety profile. There is a black box warning of
an increased risk of serious infections and malignancy.
Patients should be tested for latent tuberculosis and treated
prior to initiation of therapy, and also monitored for signs
of serious infection. Patients with chronic, active, or
untreated latent hepatitis infections were excluded from
tofacitinib clinical trials and thus the risk of chronic viral
hepatitis reactivation is unknown. Due to the immunosup-
pressive effects of tofacitinib therapy, patients should be
screened for viral hepatitis in accordance with clinical
guidelines prior to initiating therapy.16
With regards to the increased risk of malignancy, a
pooled analysis from rheumatoid arthritis trials reported
that overall rates and types of malignancy remained stable
over time with increasing exposure to tofacitinb.48 A meta-
analysis of rheumatoid arthritis trials also reported that the
risk of malignancy is similar to nonbiologic and biologic
DMARDs, concluding that tofacitinib does not increase
rate of malignancies in rheumatoid arthritis.40 However,
due to these concerns, caution should be exercised in
patients with a personal or family history of malignancy.
Longer-term studies and registries are needed to evaluate
the risk of malignancy in patients taking tofacitinib for
psoriatic arthritis.
Furthermore, there was a recent safety alert regarding
the risk of pulmonary embolism in rheumatoid arthritis
patients treated with tofacitinib 10 mg twice daily. The
36-month OPAL Balance results also reported a death due
to pulmonary embolism. Although further data are needed
to fully assess this risk, patients should be evaluated for
increased risk of a thromboembolic event prior to initiation
of therapy.17
Tofacitinib is also associated with an increased risk of
herpes zoster infection.48–51 Risk factors include increased
age, Asian race, tofacitinib dose, concomitant steroid ther-
apy, and prior biologic exposure.52 The nonlive recombi-
nant zoster vaccine (RZV) is the preferred herpes zoster
vaccine for psoriasis and psoriatic arthritis patients.
Administration is recommended prior to initiation of ther-
apy but may be safely administered during concurrent
tofacitinib treatment. The live-attenuated vaccine
(Zostavax) can also be administered but should be given
prior the start of therapy.53
Laboratory abnormalities are also associated with tofaci-
tinib use, requiring monitoring of lymphocyte, neutrophil,
hemoglobin, lipid levels, and LFTs. Since frequent monitor-
ing can be an inconvenience to patients, this should be dis-
cussed prior to initiating therapy. Due to the increased risk of
cytopenias, tofacitinib should not be initiated in patients with
an ALC of less than 500 cells/mm3, ANC of less than
1000 cells/mm3, and hemoglobin of less than 9 g/dL. A
pooled analysis of tofacitinib in patients with rheumatoid
Ly et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Psoriasis: Targets and Therapy 2019:9104
arthritis reported that patients with an ALC less than
500 cells/mm3 had an increased risk of infection and identi-
fied trends towards an increased rate of herpes zoster and
opportunistic infections with lower ALC values.54 Dosing
should be discontinued in patients with an ALC and ANC of
less than 500 cells/mm3. Treatment should be interrupted in
patients with a hemoglobin of less than 8 g/dL or a decrease
of more than 2 g/dL.16 Compared to placebo, tofacitinib was
observed to have a higher incidence of liver enzyme eleva-
tions, however, no drug-induced liver injury were reported
and incidences of ALT and AST greater than three times the
upper limit of normal were rare. Routine monitoring of liver
enzymes is recommended and elevations should be
investigated.
Of particular concern is the observed increased lipid
level, given the association between PsA and cardiovascular
disease.55 Pooled analysis from OPAL Broaden, Beyond,
and Balance reported an increased in LDL and HDL of 9–
14% for tofacitinib 5 mg and 10 mg at three and six months,
however no meaningful changes in the ratio of LDL to
HDL and total cholesterol to HDL were observed.56
Additionally, five patients experienced MACE, of which
two were fatal. A pooled analysis reported the risk of
MACE in PsA patients treated with tofacitinib to be similar
to the general PsA population.56 Long-term data is needed
to fully understand the cardiovascular risk of tofacitinib
treatment and patients with a history significant for cardio-
vascular disease should be closely evaluated.
Conclusion
Tofacitinib is an efficacious treatment option for patients
with PsA as demonstrated in two placebo-controlled phase
III RCTs using the ACR response definitions and the HAQ-
DI. In addition, tofacitinib improved patient reported out-
comes and radiographic non-progression in patients with
PsA. Tofacitinib therapy, like other biologicals, requires
monitoring by the prescribing physician. As an oral therapy,
it offers patients an alternative to injectable therapies. The
role of tofacitinib in the management of PsA will be eluci-
dated as clinical experience increases and long-term effi-
cacy and safety information become available.
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